Surgical Outcome Of da Vinci Single-port Surgical System In Lung Cancer

August 24, 2026 updated by: European Institute of Oncology
Early-stage lung cancer represents a clinical challenge that, when diagnosed promptly, offers high chances of cure through lobectomy and lymphadenectomy. In addition to traditional surgery, robotic techniques have become established and have recently evolved further with the Single-Port system, which allows the procedure to be performed through a single subcostal incision rather than multiple openings between the ribs. This approach reduces invasiveness, postoperative pain, and recovery time, while maintaining the same oncological effectiveness and safety as standard techniques. This is a monocentric and non-profit collection of clinical data, both prospective and retrospective, from patients treated with this method, ensuring data privacy through coded information and compliance with current regulations; the study is independent and non-profit.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

50

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • Italy
    • Mi
      • Milan, Mi, Italy, 20141
        • Recruiting
        • Istituto Europeo di Oncologia
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child
  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

The study will include all patients with proven non-small cell lung cancer (NSCLC) clinical stage I (9th TNM edition), who have undergone or will undergo lobectomy plus radical lymph node dissection following the STS guide line

Description

Inclusion Criteria:

  • all patients with proven non-small cell lung cancer (NSCLC) clinical stage I (9th TNM edition), who have undergone or will undergo lobectomy plus radical lymph node dissection following the STS guide line

Exclusion Criteria:

  • no consent

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
Surgical patient
Procedure: da Vinci Single Port
U-RATS lobectomy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of experience
Time Frame: "From enrollment to the end of 5 year follow-up
The objective of this study is to collect and describe IEO experiences in the use of the Da Vinci SP surgical system for anatomical lung resection.
"From enrollment to the end of 5 year follow-up

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

European Institute of Oncology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 2, 2026

Primary Completion (Estimated)

March 1, 2032

Study Completion (Estimated)

December 1, 2032

Study Registration Dates

First Submitted

April 16, 2026

First Submitted That Met QC Criteria

August 24, 2026

First Posted (Actual)

August 27, 2026

Study Record Updates

Last Update Posted (Actual)

August 27, 2026

Last Update Submitted That Met QC Criteria

August 24, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • UID 5326
  • L2-567 (Other Identifier: Comitato Etico Territoriale Lombardia 2)

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

YES

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe